Objective: To investigate the clinical efficacy of Zishen Roujing decoction in improving non-motor symptoms liver-kidney Yin deficiency syndrome in patients with Parkinson's disease

and explore its effect on adiponectin (APN)

uric acid(UA)

tumor necrosis factor (TNF)-α

and interleukin(IL)-6 levels. Method: One hundred and eight eligible cases were selected and randomly divided into control group and treatment group according to random number table

54 cases in each group. Patients in control group were treated with madopar tablets

1 tablet/time and tid. Based on the treatment in control group. Patients in treatment group also received Zishen Roujing decoction

1 dose/d and bid. The treatment course was 12 weeks for all patients. Scores of traditional Chinese medicine (TCM) symptoms

scores of non-motor symptoms questionnaire (NMSQuest)

scores of parkinson disease sleep scale (PDSS)

and scores of hamilton depression scale (HAMD) were compared between two groups. Clinical efficacy was analyzed between two groups after 12 weeks' treatment. The levels of APN

UA

TNF-α

and IL-6 in serum were detected in both groups. Result: After treatment

TCM symptom scores in treatment group were significantly lower than those of control group (P<0.01). Total effective rate was 87.04% in treatment group

significantly higher than 68.52% in control group (P<0.05). Scores of NMSQuest and HAMD in treatment group were significantly lower than those of control group

and PDSS scores were significantly higher than those of control group after treatment (P<0.01). After 6 and 12 weeks' treatment

Levels of APN and UA in serum of treatment group were higher

while TNF-α and IL-6 levels were significantly lower than those of control group (P<0.01). Conclusion: Based on western medicine

Zishen Roujing decoction in improving non-motor symptoms liver-kidney Yin deficiency syndrome in patients with Parkinson's disease could remarkably improve TCM symptoms and non-motor symptoms

and enhance clinical efficacy. Its mechanism may be associated with up-regulating APN and UA levels and down-regulating TNF-α

and IL-6 levels in serum.